E O Masini1, J Sitienei1, H Weyeinga1. 1. Division of Leprosy, Tuberculosis and Lung Diseases, Ministry of Health, Kenya.
Abstract
SETTING: Three human immunodeficiency virus (HIV) care clinics in Eastern Province, Kenya. OBJECTIVES: To establish rates of treatment completion, loss to follow-up, adverse drug reactions, tuberculosis (TB) disease and mortality among 606 HIV-infected children during 6 months of isoniazid preventive therapy (IPT). DESIGN: Retrospective record review. RESULTS: Of 606 HIV-infected children started on IPT, 556 (91.7%) successfully completed treatment, while 20 (3.3%) completed with interruptions. Cumulatively, 30 children (4.9%) did not complete IPT: 4 (0.7%) were lost to follow-up, 4 (0.7%) discontinued because of treatment interruptions, 2 (0.3%) developed adverse drug reactions, 1 developed a chronic cough, 1 was transferred to a non-IPT facility and 18 (3%) developed TB, including 2 who eventually died. TB disease was diagnosed in a median of 3 weeks (interquartile range [IQR] 2-16) post-IPT initiation. The median CD4 cell count for those aged 1-4 years who developed TB disease was 1023 cells/mm(3) (IQR 375-1432), while for those aged 5-14 years it was 149 cells/mm(3) (IQR 16-332). Isoniazid resistance was not detected in the four culture-confirmed TB cases. CONCLUSION: The high treatment completion, low loss to follow-up rate and few adverse drug reactions affirm the feasibility of IPT provision to children in HIV care clinics.
SETTING: Three human immunodeficiency virus (HIV) care clinics in Eastern Province, Kenya. OBJECTIVES: To establish rates of treatment completion, loss to follow-up, adverse drug reactions, tuberculosis (TB) disease and mortality among 606 HIV-infectedchildren during 6 months of isoniazid preventive therapy (IPT). DESIGN: Retrospective record review. RESULTS: Of 606 HIV-infectedchildren started on IPT, 556 (91.7%) successfully completed treatment, while 20 (3.3%) completed with interruptions. Cumulatively, 30 children (4.9%) did not complete IPT: 4 (0.7%) were lost to follow-up, 4 (0.7%) discontinued because of treatment interruptions, 2 (0.3%) developed adverse drug reactions, 1 developed a chronic cough, 1 was transferred to a non-IPT facility and 18 (3%) developed TB, including 2 who eventually died. TB disease was diagnosed in a median of 3 weeks (interquartile range [IQR] 2-16) post-IPT initiation. The median CD4 cell count for those aged 1-4 years who developed TB disease was 1023 cells/mm(3) (IQR 375-1432), while for those aged 5-14 years it was 149 cells/mm(3) (IQR 16-332). Isoniazid resistance was not detected in the four culture-confirmed TB cases. CONCLUSION: The high treatment completion, low loss to follow-up rate and few adverse drug reactions affirm the feasibility of IPT provision to children in HIV care clinics.
Entities:
Keywords:
adverse drug reactions; isoniazid prophylaxis; loss to follow-up; treatment completion; tuberculosis
Authors: V F Gomes; C Wejse; I Oliveira; A Andersen; F J Vieira; L J Carlos; C S Vieira; P Aaby; P Gustafson Journal: Int J Tuberc Lung Dis Date: 2011-12 Impact factor: 2.373
Authors: Kathleen R Page; Frangiscos Sifakis; Ruben Montes de Oca; Wendy A Cronin; Meg C Doherty; Lynn Federline; Sarah Bur; Thomas Walsh; Walter Karney; James Milman; Nancy Baruch; Akintoye Adelakun; Susan E Dorman Journal: Arch Intern Med Date: 2006-09-25
Authors: Heather J Zar; Mark F Cotton; Stanzi Strauss; Janine Karpakis; Gregory Hussey; H Simon Schaaf; Helena Rabie; Carl J Lombard Journal: BMJ Date: 2006-11-03
Authors: Ben J Marais; Robert P Gie; Anneke C Hesseling; H Simon Schaaf; Carl Lombard; Donald A Enarson; Nulda Beyers Journal: Pediatrics Date: 2006-11 Impact factor: 7.124
Authors: Dick Menzies; Richard Long; Anete Trajman; Marie-Josée Dion; Jae Yang; Hamdan Al Jahdali; Ziad Memish; Kamran Khan; Michael Gardam; Vernon Hoeppner; Andrea Benedetti; Kevin Schwartzman Journal: Ann Intern Med Date: 2008-11-18 Impact factor: 25.391
Authors: I Pathmanathan; S Ahmedov; E Pevzner; G Anyalechi; S Modi; H Kirking; J S Cavanaugh Journal: Int J Tuberc Lung Dis Date: 2018-06-01 Impact factor: 2.373
Authors: Dickens Otieno Onyango; Marianne A B van der Sande; Courtney M Yuen; Jerphason Mecha; Daniel Matemo; Elizabeth Oele; John Kinuthia; Grace John-Stewart; Sylvia M LaCourse Journal: J Int AIDS Soc Date: 2022-08 Impact factor: 6.707